Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Profitable Debt-Free Cash-Rich CPH at 0.8x its EBITDA!!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(79)
•••
Comment by Stocker46on Mar 23, 2021 4:41pm
193 Views
Post# 32860275

RE:RE:RE:RE:RE:RE:RE:RE:RE:Profitable Debt-Free Cash-Rich CPH at 0.8x its EBITDA!!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:Profitable Debt-Free Cash-Rich CPH at 0.8x its EBITDA!!!Bit of a rollercoaster today. Took a dive around 11 am  along with the market.

Looking back over the last few years , the last time they had quarterly net earnings this high (excluding the impairment charge) was the 4th Q of 2017. At that time they had $28M in cash but also $18M in debt. .. now $9M in cash & no debt.
After the 4th Q of 2017, Cipher was trading as high as $4.75.

They've had a number of smaller impairment charges in recent years. Hopefully future ones will be small & unplentiful.
Seems like they're in as good shape now (going in to 2021) as they've ever been. Those who have followed the Company for a few years & are more knowledgeable than I, may have a different perspective.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities